CMS121 |
Catalog No.GC40632
One-Click Copy Product Info
|
CMS121 is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353224-53-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CMS121 is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor [1]. CMS121 exerts potent neuroprotective, anti-inflammatory, antioxidant, and renal protective effects by elevating acetyl-CoA levels and activating AMPK [2-3]. CMS121 is primarily intended for the treatment of Alzheimer's-like neurodegenerative disorders [4].
In SH-SY5Y cells, CMS121 (5μM; 48h) reduces the infectivity of HSV-1 viral particles [5]. In hepatocytes, CMS12 (1μM; 24h) increases ac-STAT3 and p-STAT3 levels [6].
In male db/db mice, long-term CMS121 (9.4mg/kg, 18.8mg/kg; po; 24 weeks) treatment alleviates metabolic imbalance, liver inflammation, and reduces markers of kidney injury [7]. In SAMP8 mice model, treated with CMS121 (17mg/kg; po; 9 weeks) showed significantly reduced auditory brainstem responses threshold drift and increased preservation of inner hair cell ribbon synapses in the mid-frequency range [8].
References:
[1]. Dafre A L, Zahid S, Probst J J, et al. CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction[J]. Aging (Albany NY), 2024, 16(6): 4980.
[2]. Dong J, Li M, Peng R, et al. ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK-PPARα-CPT1A axis[J]. Journal of Translational Medicine, 2024, 22(1): 196.
[3]. Currais A, Huang L, Petrascheck M, et al. A chemical biology approach to identifying molecular pathways associated with aging[J]. GeroScience, 2021, 43(1): 353-365.
[4]. Currais A, Raschke W, Maher P. CMS121, a novel drug candidate for the treatment of Alzheimer’s disease and age-related dementia[J]. Journal of Alzheimer’s Disease, 2024, 101(s1): S179-S192.
[5]. Albano C, Trifirò L, Hewelt-Belka W, et al. The impact of fatty acid synthase on HSV-1 infection dynamics[J]. PLoS pathogens, 2025, 21(5): e1013068.
[6]. He Y, Wang S, Liu S, et al. MSL1 promotes liver regeneration by driving phase separation of STAT3 and histone h4 and enhancing their acetylation[J]. Advanced Science, 2023, 10(23): 2301094.
[7]. Zahid S, Dafre A L, Currais A, et al. The geroprotective drug candidate CMS121 alleviates diabetes, liver inflammation, and renal damage in db/db leptin receptor deficient mice[J]. International Journal of Molecular Sciences, 2023, 24(7): 6828.
[8]. Pham T B, Boussaty E C, Currais A, et al. Attenuation of age-related hearing impairment in senescence-accelerated mouse prone 8 (SAMP8) mice treated with fatty acid synthase inhibitor CMS121[J]. Journal of Molecular Neuroscience, 2023, 73(4): 307-315.
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells |
Preparation Method | To determine the cytotoxicity of CMS121, SH-SY5Y cells were seeded in a 96-well culture plate and exposed to increasing concentrations of either compounds or vehicle dimethyl sulfoxide (DMSO) the following day. After 48h of incubation, the number of viable cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Similarly, shCTRL and shFASN cells were grown to confluence. The medium was then replaced with serum-free medium, and after 48 hours, the number of viable cells was measured using the MTT assay. |
Reaction Conditions | 5μM; 48h |
Applications | CMS121 reduces the infectivity of HSV-1 viral particles. |
| Animal experiment [2]: | |
Animal models | Male db/db mice |
Preparation Method | At 5 weeks of age, male db/db mice and untreated wild-type (WT) mice (C57BL/6J) were fed a standard rodent diet for 6 months with or without the addition of CMS121. Mice (12 per group) were randomly assigned to a treatment diet group (db/db + CMS121) or a control group (db/db). WT mice were also evaluated and used as a reference group to highlight the db/db phenotype. Food intake corresponded to an average consumption of 9.4mg/kg/day CMS121 during the first 17 weeks of treatment and an average consumption of 18.8mg/kg/day CMS121 during weeks 18-24. |
Dosage form | 9.4mg/kg, 18.8mg/kg; po; 24 weeks |
Applications | Long-term CMS121 treatment alleviates metabolic imbalance, liver inflammation, and reduces markers of kidney injury. |
References: | |
| Cas No. | 1353224-53-9 | SDF | |
| Chemical Name | 4-[4-(cyclopentyloxy)-2-quinolinyl]-1,2-benzenediol | ||
| Canonical SMILES | OC1=CC(C2=NC(C=CC=C3)=C3C(OC4CCCC4)=C2)=CC=C1O | ||
| Formula | C20H19NO3 | M.Wt | 321.4 |
| Solubility | 20mg/mL in DMSO, 30mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1114 mL | 15.5569 mL | 31.1139 mL |
| 5 mM | 622.3 μL | 3.1114 mL | 6.2228 mL |
| 10 mM | 311.1 μL | 1.5557 mL | 3.1114 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)